Ledipasvir-sofosbuvir for hepatitis C genotype 4 infection

Affiliations

¹ University of the Sciences in Philadelphia, Philadelphia College of Pharmacy, Philadelphia, PA, USA.
² University of Michigan College of Pharmacy, UMHS Pharmacy Services, Ann Arbor, MI 48109-2054, USA. Electronic address: rimam@umich.edu.

Comment

Michael A Smith et al. Lancet Infect Dis. 2015 Sep.

. 2015 Sep;15(9):993-995.

doi: 10.1016/S1473-3099(15)00223-6. Epub 2015 Jul 14.

¹ University of the Sciences in Philadelphia, Philadelphia College of Pharmacy, Philadelphia, PA, USA.
² University of Michigan College of Pharmacy, UMHS Pharmacy Services, Ann Arbor, MI 48109-2054, USA. Electronic address: rimam@umich.edu.

No abstract available

Comment on

Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.
Kohli A, Kapoor R, Sims Z, Nelson A, Sidharthan S, Lam B, Silk R, Kotb C, Gross C, Teferi G, Sugarman K, Pang PS, Osinusi A, Polis MA, Rustgi V, Masur H, Kottilil S. Kohli A, et al. Lancet Infect Dis. 2015 Sep;15(9):1049-1054. doi: 10.1016/S1473-3099(15)00157-7. Epub 2015 Jul 14. Lancet Infect Dis. 2015. PMID: 26187031 Free PMC article. Clinical Trial.